The hardest part is usually the first sentence. You have ten or fifteen minutes with your doctor, the visit was booked for something else, and the thing you most want to ask is the thing you are least sure how to phrase.
This page is a script, not to recite word for word, but a set of sentences that earn a real answer instead of a polite nod. It rests on a finding from our own research: when 443 adults across ten Midwest states were asked what would bring them to try ketamine-type therapy, 74 percent pointed to a recommendation from their own doctor, and advertising moved 2 percent. If the exam room is where this gets decided, that is where preparation belongs.
Open with the history, not the treatment
Leading with a drug name can sound like a request for a specific prescription. Leading with your history sounds like a clinical problem to solve, which is the conversation you want.
Try: "I want to talk about my depression today, specifically that I have been on medication and I am still not functioning the way I need to. Can we spend the visit on that?"
Booking with that purpose helps more. When you call the office, in St. Charles or wherever you get care, say the appointment concerns depression that medication has not moved; front desks route those requests differently from a general check-in, and you may get a longer slot.
Bring the medication timeline
Treatment-resistant depression is not a mood; it is a documented pattern of adequate trials that did not work, and your doctor cannot rebuild it from memory in a short visit. Write it down, with each medication's rough dose, trial length, and reason for stopping.
Try: "Here is everything I have tried and what happened with each one. Based on this, would you consider my depression treatment resistant?"
Ask the approval question out loud
Regulatory standing mattered enormously to the people we surveyed. Of our respondents, 19 percent would let FDA approval decide the matter and 40 percent would weigh it heavily, 59 percent in all; 27 percent rated it somewhat important, and 14 percent were indifferent.
That matters because two different things share a nickname. Spravato, the esketamine spray, holds an FDA approval specific to treatment-resistant depression, and patients receive it only in supervised sessions at certified sites; ketamine by infusion, or shipped home by an online provider, is a different arrangement with different oversight. Nobody should have to guess which one is on offer. Brain Recovery Centers publishes a patient overview of its Spravato program if you want to see how a certified clinic explains it.
Try: "If we were to consider this, would you be talking about the FDA-approved esketamine given in a certified clinic, or something else? I want to understand the difference before I go any further."
Ask what has to happen first
Most plans want documentation before approving anything in this category, so ask about the sequence early and skip a month of dead ends.
Try: "If I am not eligible today, what would need to be true for me to be eligible? How many medication trials, and over what period?"
Also ask: "Who would you send me to for this? Is there someone you trust in the St. Charles area or in the wider metro?"
A named referral beats a list of clinics. It keeps your records moving and gives the receiving clinician context a self-referral lacks.
Describe how it feels, not how you think it should sound
Our open-text question drew 319 answers, and they were plain: "best ways to handle depression," "ptsd help," "depression medicine alternatives." Nobody performed medical fluency; they described a problem and asked for a hand.
Bring that plainness into the visit. "I sleep nine hours and wake up exhausted." "I have not answered a friend's text in two months." "I can do work but I cannot do anything after work." Specifics like these say more than the word depressed.
If your doctor is unfamiliar with it
Most of the public is unfamiliar too. In our survey, Spravato was a blank for 73 percent and a bare name for 21 percent; only 6 percent could say what it was. A physician who wants to read before answering is being reasonable, not dismissive.
Try: "I understand if this is not your area. Would you be willing to look into it and follow up, or refer me to someone who prescribes it?"
Ask for the follow-up through the patient portal so the thread does not die when you leave.
If the answer is no
Ask for the reason and take it seriously. There are genuine medical reasons someone may not be a candidate, including blood pressure, certain heart conditions, some psychiatric histories, and pregnancy, and a clear reason is useful even when disappointing.
Try: "Can you help me understand what rules it out in my case? And if I wanted a psychiatrist's opinion on that, would you refer me?"
Seeking a second opinion is routine, not a verdict on your relationship with your primary doctor.
You are not an outlier for asking
Carry one more result into the room. Among our respondents, 72 percent had faced depression, anxiety, or PTSD that routine medication left standing, personally for 37 percent, through a loved one for 22 percent, and both ways for 13 percent, while 28 percent had not. Nearly three in four people had brushed against the problem you are bringing in.
Nothing on this page is medical advice or a recommendation to pursue any treatment. Whether something is right for you depends on health facts only a clinician who examines you can weigh.
And if any of this has grown heavier than a treatment question, please do not sit with it alone. Thoughts of suicide are a reason to reach out now, not at the next available appointment. By call or text, 988 reaches the Lifeline at any hour, free. Say it to someone today; being honest about it is how people get through.
Methodology
The figures come from a survey this site's publisher commissioned and paid for. Pollfish fielded it on its consumer panel through late June; at the June 23, 2026 close, 443 adults, 18 through 64, had taken part from ten Midwest states; they were drawn from the public at large, and each cleared a consent screener. On multiple-answer questions the shares are of respondents, so totals can exceed 100. All results come from the panel's final validation pass.